Acadia Pharmaceuticals Inc (ACAD) Actualités

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia’s Board of Directors...

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

- Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers...

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22nd...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments